Tokyo Tape
Sign in
← Chiome Bioscience

Annual report

4583.TEDINET S100QGF6
Period2022-01-01 → 2022-12-31
Filed2023-03-28
StandardJapan GAAP
ConsolidatedNo
Data checks13 of 13 passed
Key figures · 76
MetricValuePeriodScopeSource row
Revenue¥631m2022-01-01 → 2022-12-31StandaloneNet sales
Revenue¥713m2021-01-01 → 2021-12-31StandaloneNet sales
Revenue¥481m2020-01-01 → 2020-12-31dStandaloneNet sales (5-year summary)
Revenue¥448m2019-01-01 → 2019-12-31dStandaloneNet sales (5-year summary)
Revenue¥213m2018-01-01 → 2018-12-31dStandaloneNet sales (5-year summary)
Operating income−¥1.3bn2022-01-01 → 2022-12-31StandaloneOperating income
Operating income−¥1.3bn2021-01-01 → 2021-12-31StandaloneOperating income
Ordinary income−¥1.2bn2022-01-01 → 2022-12-31StandaloneOrdinary income
Ordinary income−¥1.3bn2021-01-01 → 2021-12-31StandaloneOrdinary income
Ordinary income−¥1.3bn2020-01-01 → 2020-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥1.4bn2019-01-01 → 2019-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥1.5bn2018-01-01 → 2018-12-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax−¥1.2bn2022-01-01 → 2022-12-31StandaloneIncome before income taxes
Profit before tax−¥1.5bn2021-01-01 → 2021-12-31StandaloneIncome before income taxes
Net income−¥1.2bn2022-01-01 → 2022-12-31StandaloneProfit loss
Net income−¥1.5bn2021-01-01 → 2021-12-31StandaloneProfit loss
Net income−¥1.3bn2020-01-01 → 2020-12-31dStandaloneNet income loss (5-year summary)
Net income−¥1.4bn2019-01-01 → 2019-12-31dStandaloneNet income loss (5-year summary)
Net income−¥1.5bn2018-01-01 → 2018-12-31dStandaloneNet income loss (5-year summary)
Total assets¥2.2bnat 2022-12-31StandaloneAssets
Total assets¥2.3bnat 2021-12-31StandaloneAssets
Total assets¥3.5bnat 2020-12-31dStandaloneTotal assets (5-year summary)
Total assets¥2.8bnat 2019-12-31dStandaloneTotal assets (5-year summary)
Total assets¥2.8bnat 2018-12-31dStandaloneTotal assets (5-year summary)
Total liabilities¥425mat 2022-12-31StandaloneLiabilities
Total liabilities¥446mat 2021-12-31StandaloneLiabilities
Net assets / equity¥1.8bnat 2022-12-31StandaloneNet assets
Net assets / equity¥1.9bnat 2021-12-31StandaloneNet assets
Net assets / equity¥3.1bnat 2020-12-31dStandaloneNet assets
Net assets / equity¥2.6bnat 2019-12-31dStandaloneNet assets (5-year summary)
Net assets / equity¥2.7bnat 2018-12-31dStandaloneNet assets (5-year summary)
Cash and deposits¥1.7bnat 2022-12-31StandaloneCash and deposits
Cash and deposits¥1.8bnat 2021-12-31StandaloneCash and deposits
Cash & equivalents¥1.7bnat 2022-12-31StandaloneCash and cash equivalents
Cash & equivalents¥1.8bnat 2021-12-31StandaloneCash and cash equivalents
Cash & equivalents¥2.7bnat 2020-12-31dStandaloneCash and cash equivalents
Cash & equivalents¥2.1bnat 2019-12-31dStandaloneCash and cash equivalents (5-year summary)
Cash & equivalents¥2.3bnat 2018-12-31dStandaloneCash and cash equivalents (5-year summary)
Operating cash flow−¥1.2bn2022-01-01 → 2022-12-31StandaloneNet cash provided by used in operating activities
Operating cash flow−¥1.1bn2021-01-01 → 2021-12-31StandaloneNet cash provided by used in operating activities
Operating cash flow−¥1.4bn2020-01-01 → 2020-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥1.5bn2019-01-01 → 2019-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥1.7bn2018-01-01 → 2018-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Investing cash flow−¥35m2021-01-01 → 2021-12-31StandaloneNet cash provided by used in investment activities
Investing cash flow−¥4m2020-01-01 → 2020-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow−¥26m2019-01-01 → 2019-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Financing cash flow¥1.1bn2022-01-01 → 2022-12-31StandaloneNet cash provided by used in financing activities
Financing cash flow¥271m2021-01-01 → 2021-12-31StandaloneNet cash provided by used in financing activities
Financing cash flow¥1.9bn2020-01-01 → 2020-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥1.3bn2019-01-01 → 2019-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow−¥10m2018-01-01 → 2018-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
EPS (basic)¥-28.262022-01-01 → 2022-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-36.742021-01-01 → 2021-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-36.062020-01-01 → 2020-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-44.612019-01-01 → 2019-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-57.262018-01-01 → 2018-12-31dStandaloneBasic earnings loss per share (5-year summary)
Net assets per share¥36.7at 2022-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥45.55at 2021-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥77.99at 2020-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥78.1at 2019-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥98.89at 2018-12-31dStandaloneNet assets per share (5-year summary)
Equity ratio80.2%at 2022-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio79.4%at 2021-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio88.2%at 2020-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio92.6%at 2019-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio93.5%at 2018-12-31dStandaloneEquity to asset ratio (5-year summary)
Shares issued48,423,500at 2022-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued40,781,500at 2021-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued39,505,200at 2020-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued33,283,500at 2019-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued26,781,500at 2018-12-31dStandaloneTotal number of issued shares (5-year summary)
Employees49at 2022-12-31StandaloneNumber of employees
Employees49at 2021-12-31StandaloneNumber of employees
Employees42at 2020-12-31dStandaloneNumber of employees
Employees38at 2019-12-31dStandaloneNumber of employees
Employees37at 2018-12-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 21
SegmentItemPeriodValue
Reconciling Itemsreconcilingsegment assetsat 2022-12-31¥2.2bn
Reconciling Itemsreconcilingsegment profit2022-01-01 → 2022-12-31−¥472m
Drug Discovery And Developmentreportable segmentsegment profit2022-01-01 → 2022-12-31−¥1.1bn
Drug Discovery Supportreportable segmentrevenue2022-01-01 → 2022-12-31¥631m
Drug Discovery Supportreportable segmentrevenue external2022-01-01 → 2022-12-31¥631m
Drug Discovery Supportreportable segmentsegment profit2022-01-01 → 2022-12-31¥349m
—segment totalemployeesat 2022-12-3139 pure
Total Of Reportable Segments And Otherssegment totalrevenue2022-01-01 → 2022-12-31¥631m
Total Of Reportable Segments And Otherssegment totalrevenue external2022-01-01 → 2022-12-31¥631m
Total Of Reportable Segments And Otherssegment totalsegment profit2022-01-01 → 2022-12-31−¥787m
Reconciling Itemsreconcilingsegment assetsat 2021-12-31¥2.3bn
Reconciling Itemsreconcilingsegment profit2021-01-01 → 2021-12-31−¥445m
Drug Discovery And Developmentreportable segmentrevenue2021-01-01 → 2021-12-31¥103m
Drug Discovery And Developmentreportable segmentrevenue external2021-01-01 → 2021-12-31¥103m
Drug Discovery And Developmentreportable segmentsegment profit2021-01-01 → 2021-12-31−¥1.2bn
Drug Discovery Supportreportable segmentrevenue2021-01-01 → 2021-12-31¥610m
Drug Discovery Supportreportable segmentrevenue external2021-01-01 → 2021-12-31¥610m
Drug Discovery Supportreportable segmentsegment profit2021-01-01 → 2021-12-31¥320m
Total Of Reportable Segments And Otherssegment totalrevenue2021-01-01 → 2021-12-31¥713m
Total Of Reportable Segments And Otherssegment totalrevenue external2021-01-01 → 2021-12-31¥713m
Total Of Reportable Segments And Otherssegment totalsegment profit2021-01-01 → 2021-12-31−¥890m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 834
ItemContextValueUnit
Independent auditors report non consolidated (text)FilingDateInstantText · Plus
Audit firm1 non consolidatedFilingDateInstant
Original text (Japanese)有 限 責 任 監 査 法 人 ト ー マ ツ
Cpa1 audit firm1 non consolidatedFilingDateInstant
Original text (Japanese)鈴　木　基　之
Cpa2 audit firm1 non consolidatedFilingDateInstant
Original text (Japanese)三　浦　靖　晃
Key audit matters non consolidated (text)FilingDateInstantText · Plus
Overview kam non consolidated (text)FilingDateInstantText · Plus
Short description kam non consolidatedFilingDateInstant_Row1Member
Original text (Japanese)委託研究費（研究開発費）の期間帰属の適切性
Description including reason kam non consolidated (text)FilingDateInstant_Row1MemberText · Plus
Reference kam non consolidatedFilingDateInstant_Row1Member
Original text (Japanese)2022年12月期の損益計算書
Reference2 kam non consolidatedFilingDateInstant_Row1Member
Original text (Japanese)注記事項「（損益計算書関係）※１」
Auditors response kam non consolidated (text)FilingDateInstant_Row1MemberText · Plus
Other information non consolidated (text)FilingDateInstantText · Plus
Number of submissionFilingDateInstant1
Net sales (5-year summary)Prior4YearDuration_NonConsolidatedMember212851000JPY
Net sales (5-year summary)Prior3YearDuration_NonConsolidatedMember447576000JPY
Net sales (5-year summary)Prior2YearDuration_NonConsolidatedMember480853000JPY
Net sales (5-year summary)Prior1YearDuration_NonConsolidatedMember712932000JPY
Net sales (5-year summary)CurrentYearDuration_NonConsolidatedMember630815000JPY
Ordinary income loss (5-year summary)Prior4YearDuration_NonConsolidatedMember-1533952000JPY
Ordinary income loss (5-year summary)Prior3YearDuration_NonConsolidatedMember-1410314000JPY
Ordinary income loss (5-year summary)Prior2YearDuration_NonConsolidatedMember-1291606000JPY
Ordinary income loss (5-year summary)Prior1YearDuration_NonConsolidatedMember-1329312000JPY
Ordinary income loss (5-year summary)CurrentYearDuration_NonConsolidatedMember-1243838000JPY
Net income loss (5-year summary)Prior4YearDuration_NonConsolidatedMember-1533502000JPY
Net income loss (5-year summary)Prior3YearDuration_NonConsolidatedMember-1403821000JPY
Net income loss (5-year summary)Prior2YearDuration_NonConsolidatedMember-1293798000JPY
Net income loss (5-year summary)Prior1YearDuration_NonConsolidatedMember-1479895000JPY
Net income loss (5-year summary)CurrentYearDuration_NonConsolidatedMember-1242871000JPY
Equity in earnings losses of affiliates if equity method is applied (5-year summary)Prior4YearDuration_NonConsolidatedMember－JPY
Equity in earnings losses of affiliates if equity method is applied (5-year summary)Prior3YearDuration_NonConsolidatedMember－JPY
Equity in earnings losses of affiliates if equity method is applied (5-year summary)Prior2YearDuration_NonConsolidatedMember－JPY
Equity in earnings losses of affiliates if equity method is applied (5-year summary)Prior1YearDuration_NonConsolidatedMember－JPY
Equity in earnings losses of affiliates if equity method is applied (5-year summary)CurrentYearDuration_NonConsolidatedMember－JPY
Capital stock (5-year summary)Prior4YearInstant_NonConsolidatedMember5454775000JPY
Capital stock (5-year summary)Prior3YearInstant_NonConsolidatedMember6132216000JPY
Capital stock (5-year summary)Prior2YearInstant_NonConsolidatedMember1387677000JPY
Capital stock (5-year summary)Prior1YearInstant_NonConsolidatedMember1515929000JPY
Capital stock (5-year summary)CurrentYearInstant_NonConsolidatedMember2097017000JPY
Total number of issued shares (5-year summary)Prior4YearInstant_NonConsolidatedMember26781500
Total number of issued shares (5-year summary)Prior3YearInstant_NonConsolidatedMember33283500
Total number of issued shares (5-year summary)Prior2YearInstant_NonConsolidatedMember39505200
Total number of issued shares (5-year summary)Prior1YearInstant_NonConsolidatedMember40781500
Total number of issued shares (5-year summary)CurrentYearInstant_NonConsolidatedMember48423500
Net assets (5-year summary)Prior4YearInstant_NonConsolidatedMember2676719000JPY
Net assets (5-year summary)Prior3YearInstant_NonConsolidatedMember2621508000JPY
Net assets (5-year summary)Prior2YearInstant_NonConsolidatedMember3109968000JPY
Net assets (5-year summary)Prior1YearInstant_NonConsolidatedMember1893049000JPY
Net assets (5-year summary)CurrentYearInstant_NonConsolidatedMember1790746000JPY
Total assets (5-year summary)Prior4YearInstant_NonConsolidatedMember2831193000JPY
Total assets (5-year summary)Prior3YearInstant_NonConsolidatedMember2808090000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 13 of 13 passed
balance sheet identitynon_consolidated 2021-12-31pass
balance sheet identitynon_consolidated 2022-12-31pass
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2020-12-31pass
statement vs summary · net assetsnon_consolidated 2021-12-31pass
statement vs summary · net assetsnon_consolidated 2022-12-31pass
statement vs summary · operating cash flownon_consolidated 2021-01-01/2021-12-31pass
statement vs summary · operating cash flownon_consolidated 2022-01-01/2022-12-31pass
statement vs summary · revenuenon_consolidated 2021-01-01/2021-12-31pass
statement vs summary · revenuenon_consolidated 2022-01-01/2022-12-31pass
statement vs summary · total assetsnon_consolidated 2021-12-31pass
statement vs summary · total assetsnon_consolidated 2022-12-31pass